Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.53 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: at-7519, milciclib, azd-5438 +14 | 1.00 |
| trials ClinicalTrials.gov | 1 Parkinson's trial, 1 stopped | 0.20 |
| literature PubMed | 19 Parkinson's papers of 13,547 | 0.61 |
| pathways Reactome | 19 pathways; mostly protein handling | 0.90 |
No case: the score is under the bar. Receipt 11471
Earlier readings: 2026-10-26 0.44; 2026-10-25 0.44; 2026-10-24 0.44; 2026-10-23 0.44.
Sealed predictions
- CDK4 in dopamine neurons, braak+0.09 (p 0.825) → +0.45 (p 0.219)receipt 0177
Swarm cases
receipt 0177: CDK4 in dopamine neurons, braak
- power
- full sample +0.17 (p 0.493, n 18), 95% CI -0.32 to +0.59. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.22 (p 0.384, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.23 (p 0.369, n 18). could be the mix.
- skeptic
- leave-one-out range +0.06 to +0.35, sign flips 0; without severely affected donors +0.17 (p 0.493, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CDK4 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts